Objective Diabetes is a major risk factor for chronic kidney disease (CKD). In this study, we examined the effects of alogliptin on blood glucose control and the renal function in type 2 diabetes CKD patients. Methods We recruited 36 CKD patients with type 2 diabetes. The patients were followed up for six months after adding alogliptin. Blood biochemical, urine test and office BP values were obtained six months before and after the start of treatment. Results The mean HbA1c value was not decreased; however, the 1,5-AG values tended to improve (p= 0.1023). The mean eGFR was unchanged. There were no significant changes in the patients with an eGFR of 60 mL/min/1.73 m 2 or more (25 patients) or in the patients with an eGFR less than 60 mL/min/1.73 m 2 (11 patients). A total of 15 patients were identified to have rapidly declining diabetic nephropathy, with an annual reduction in eGFR of 5 mL/min/1.73 m 2 or more. The slope of the regression line for eGFR (-1.296 before starting treatment with alogliptin) was positive, increasing up to 0.08786. The eGFR values appeared to stop decreasing and positively reversed. The urinary albumin-to-creatinine ratio exhibited a downward trend. The effect on the renal function was independent of the levels of blood sugar, blood pressure and lipids. Conclusion We examined the ability of alogliptin to maintain the renal function in patients with CKD complicated by type 2 diabetes. Our study suggests that alogliptin can be safely administered in patients with CKD. However, although we expected alogliptin to demonstrate renal protective effects, were unable to detect statistically significant differences. One reason for this finding is that there are few registered cases.
Introduction
Diabetes is a risk factor for a reduced renal function (1) . Deterioration of the renal function is known to be an important risk factor for cardiovascular events and diabetes (2) . In order to reduce these risk factors, it is important to control the blood glucose levels while avoiding possible hypoglycemia in patients with diabetes in the early stages of the disease (3) (4) (5) (6) . Elderly patients with diabetes and those who have suffered from the disease for a long time, however, often experience deterioration of the renal function (7) . Indeed, patients with diabetes whose renal function is deteriorated have more hypoglycemic episodes (8) (9) (10) . Therefore, diabetes treatment must address the possible effects of a reduced renal function in patients with diabetes (11, 12) .
Among the recently launched diabetes drugs that have achieved marked progress in treatment, oral dipeptidyl peptidase-4 (DPP-4) inhibitors ("DPP-4 inhibitors") carry a lower risk of hypoglycemia and body weight gain (13) (14) (15) (16) (17) . Their benefits in protecting the kidneys have been also reported in recent studies (18) (19) (20) (21) (22) (23) (24) . These drugs have attracted extensive interest as promising new alternatives to existing diabetes drugs in patients with diabetes and a reduced renal function.
To obtain further insight into the efficacy of DPP-4 inhibitors, we examined the effects of alogliptin on blood glucose control and the renal function in patients with chronic kidney disease (CKD) complicated by type 2 diabetes.
Materials and Methods
This was a retrospective observational exploratory study performed in type 2 diabetes patients who had attended the Nippon Medical School Musashikosugi Hospital between November 2011 and August 2012. The study population involved all patients with CKD (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m 2 or micro albuminuria >30 mg/gCr) (25) who had been treated for diabetes for six months or longer.
The initial daily dose of alogliptin was set at 6.25 mg. The dose was increased up to 25 mg in patients whose HbA1c (National Glycohemoglobin Standardization Program [NGSP] value) (26) level did not favorably change after treatment. The patients were followed up for six months after the commencement of treatment. During the treatment and follow-up periods, no other diabetes drugs were added and no antihyperlipidemic drugs were replaced. Data regarding the HbA1c, 1,5-AG and serum creatinine levels, other blood biochemical parameters, urinalysis results and systolic and diastolic blood pressure within the six-month periods before and after the start of alogliptin treatment were extracted from the patients' medical records. The usual laboratory methods employed by the hospital were used throughout the study. The estimated GFR was calculated using a formula based on the serum creatinine level developed by the Japanese Society of Nephrology for the Japanese population (27) .
The measurement values are shown as the mean±standard deviation (mean±SD). A one-way ANOVA of the longitudinal data was performed to address multiplicity. Tukey's multiple comparison test was then used to perform the post hoc test. p values less than 0.05 were regarded to be statistically significant. Regression lines were separately determined for the data collected during the six-month period before the start of treatment and the six-month period after the start of treatment for comparison. For the various intergroup comparisons, Fisher's exact test was used. The correlations between parameters were examined using a Pearson productmoment correlation analysis. The patients were divided into two groups based on an estimated glomerular filtration rate (eGFR) of 60 mL/min/1.73 m 2 or more or an eGFR less than 60 mL/min/1.73 m 2 . In addition, regression lines were determined for the two groups for comparison.
Results
The patients' background characteristics are shown in Table 1. The subjects consisted of 24 men and 12 women. The mean (±SD; the data are hereinafter presented in this format) age was 63.0±13.1 years and the mean duration of disease was 16.3±9.1 years. The mean HbA1c level was 7.1± 1.2%, the mean 1,5-AG value was 6.0±3.6 μg/mL, the mean eGFR was 71.0±28.9 mL/min/1.73 mm 2 and the mean level of albuminuria (urinary albumin-to-creatinine ratio, UACR) was 111.5±111.1 mg/gCr. The last dose of alogliptin was 6.25 mg in five subjects and 25 mg in 31 subjects. The existing therapeutic agents included sulfonylureas in 14 subjects, a combination of sulfonylureas and thiazolidines in four subjects, insulin in seven subjects and glinides in three subjects. Eight subjects were treated with diet only. The mean BMI was 23.6±5.6 kg/m 2 , the mean systolic blood pressure was 114.0±23.9 mmHg and the mean diastolic blood pressure was 61.4±16.4 mmHg. The mean total cholesterol level was 201.7±33.6 mg/dL, the mean HDL cholesterol level was 51.7±10.0 mg/dL, the mean LDL cholesterol level was 131.4±26.2 mg/dL and the mean triglyceride level was 167.3±96.8 mg/dL. No parameters showed any significant changes during the examined period. Angiotensin receptor blockers (ARBs) and statins were used in 17 and 15 subjects, respectively. The dose of ARBs was increased in four subjects and decreased in three subjects. The dose of statins was not changed.
The mean HbA1c level was 7.2±1.1% after six months of alogliptin therapy and did not show any significant changes for 13 months (p=0.9031) ( Table 1) . However, the mean 1,5-AG improved to 9.4±7.6 μg/mL after six months of treatment, although the change was not significant (p= 0.1023). The slope of the regression line was negative (-0.3212) for the six months before treatment and positive (0.6255) after the start of treatment. The difference between the slopes of the regression lines was significant (p=0.0059) ( Fig. 1) .
We divided the subjects into two groups: those whose HbA1c level improved (improved group) and those whose HbA1c level was exacerbated (exacerbated group). The background characteristics of these two groups are shown in Table 2 . Only the TC levels demonstrated a significant difference between the improved group and the exacerbated group at baseline (p=0.0242), and only the HbA1c levels in the exacerbated group showed significant changes during the examined period (p=0.0332). In the analysis of variance of the eGFR and UACR, no significant differences were noted in any parameter in either the improved or exacerbated group (the eGFR was 0.9992 in both the improved and exacerbated groups, while the UACR was 0.8201 in the improved group and 0.8080 in the exacerbated group). No significant differences were observed in the slopes of the regression lines for eGFR and UACR between the improved group and the exacerbated group (eGFR: p=0.9825, UACR: p=0.4211) (Fig. 2) . The Pearson product-moment correlation analysis performed to identify parameters correlated with the HbA1c levels after the administration of alogliptin revealed a significant correlation with the eGFR values (Y=0.01349*X+ 6.237, r=0.3989, p=0.0160), indicating higher HbA1c levels in the subjects with a better renal function (Fig. 3) .
No major changes were observed in the eGFR values after six months; the mean eGFR was 68.5±29.2 mL/min/1.73 mm 2 . No significant differences were noted in the analysis of variance (p=0.9996) ( Table 1 ). The slope of the regression line was -0.3318 for the six months before treatment and -0.5829 for the six months after the start of treatment, with no significant differences (p=0.6439) (Fig. 4) .
The analysis of the two groups determined based on the eGFR [eGFR of 60 mL/min/1.73 m 2 or higher (25 subjects); eGFR below 60 mL/min/1.73 m 2 (11 subjects)] revealed no significant changes in either group (p=0.9982 in the former group and p=0.9149 in the latter group). The slopes of the regression lines before treatment and after the start of treatment were -0.2389 and -0.3571 in the former group and 0.1089 and -0.4257 in the latter group, respectively, without any significant differences (p=0.8419, p=0.6328) (Fig. 5) .
We considered the subjects whose eGFR decreased by 5 mL/min/1.73 m 2 per year or faster as having rapidly progressive diabetic nephropathy (rapid decliner group). A total of 15 such patients were identified based on changes in the eGFR during the six months before treatment with alogliptin (Table 3 shows the background characteristics of the rapid decliner group and the remaining subjects). In the subjects with rapid progression of renal dysfunction, the mean eGFR was 70.1±28.4 mL/min/1.73 m 2 six months before treatment with alogliptin, decreased to 64.2±25.6 mL/min/1.73 m 2 at the start of treatment and was 64.7±28.3 mL/min/1.73 m 2 six months after the start of treatment. Although the analysis of variance did not reveal any significant differences (p= 0.9992) (Table 3) , the slope of the regression line was (Fig. 6 ).
Regarding the background factors, a significant difference was observed in diastolic blood pressure (p=0.0061); i.e., the diastolic blood pressure values were significantly lower in the rapid decliner group. During the examined period, the diastolic blood pressure values in the rapid decliner group were significantly increased (p=0.0426). No other background factors demonstrated significant differences, and no other significant changes were noted during the examined period (Table 3) .
We defined the subjects whose eGFR was decreased (<60) without overt proteinuria as early decliners, identifying eight such subjects. Among these subjects, the eGFR values improved following treatment with alogliptin in four patients and were exacerbated following treatment in four patients. Among the subjects who were not early decliners, the ratio of patients exhibiting improvement to those demonstrating exacerbation was 10:18. Fisher's exact test showed a p value of 0.6832. No significant differences were observed in the rate of decrease in the eGFR between the early decliners and the other subjects (p=0.8267). A Pearson product-moment correlation analysis performed to examine the correlations between the rate of change in eGFR and each parameter revealed a significant correlation with systolic blood pressure (Y=-0.3683*X+40.71, r= -0.3761, p=0.0238), indicating a higher rate of decrease in eGFR in the subjects with higher systolic blood pressure at the start of treatment with alogliptin. No significant correlations were observed with the other parameters (Fig. 7) .
No associations were observed between the presence or absence of the administration of ARBs and the presence or absence of an improvement in the eGFR according to Fisher's exact test (p=1.0000).
The mean UACR decreased to 61.6±57.1 mg/gCr six months after the start of treatment, although the change was not significant (p=0.9869) ( Table 1) . However, the slope of the regression line (3.992 before treatment with alogliptin) became negative at -6.335 after the start of treatment, showing a tendency to decrease. The difference in the slopes of the regression lines before treatment and after the start of treatment was significant (p=0.037) (Fig. 8) .
Adverse events
A slight increase in the transaminase level was recorded in a single patient after the start of treatment with alogliptin; however, the event was not considered to be clinically significant, and the alogliptin treatment was continued.
Discussion
In the present study, we examined the effects of alogliptin in maintaining the renal function in type 2 diabetes patients with accompanying CKD.
Almost no changes in the HbA1c levels were observed following treatment with alogliptin. Possible reasons for the absence of significant changes include: 1) the Hb1Ac levels were controlled to a certain extent by existing therapeutic agents in many subjects; and 2) some subjects experienced extreme exacerbation after the start of the treatment with alogliptin. However, the 1,5-AG values showed a tendency toward improvement. Although data cannot be presented because the blood glucose profiles were not examined in detail, the changes in the 1,5-AG values suggest the possibility that alogliptin improved postprandial hyperglycemia. It is not uncommon that alpha-glucosidase inhibitors (α-GIs) specialized in treating postprandial hyperglycemia improved the 1,5-AG values to approximately 20 μg/mL without changing the HbA1c levels to be within the normal range (28) . Based on the results of the present study, we speculate that DPP-4 inhibitors also improve blood glucose variability as drugs suppressing postprandial hyperglycemia. It is particularly noteworthy that a similar effect was observed in the subjects with CKD. Nevertheless, no definitive conclusions can be drawn because patients with various types of nephropathy were enrolled in this study, which restricts the evaluation of the 1,5-AG values.
When we compared the clinical background characteristics between the improved group and the exacerbation group (defined based on HbA1c), a difference was noted in the TC levels. Therefore, the possibility that patients with higher TC levels are resistant to DPP-4 inhibitors cannot be excluded. There were no differences in the changes in eGFR or UACR between the improved group and the exacerbation group. This result does not support the hypothesis that the renal protective effects of alogliptin observed in this study depended on the blood glucose levels.
The eGFR was found to be a significant parameter correlated with the HbA1c level after the start of treatment with alogliptin. This result suggests that patients with a lower renal function have lower HbA1c levels, a finding that is commonly accepted in the daily treatment of diabetic patients based on the drug metabolism in the kidneys.
Regarding the eGFR, the slope of the regression line was approximately 0 throughout the entire study period, indicating that the eGFR values were stable throughout the 13 months. As many subjects were eventually treated at a dose of 25 mg, it can be speculated that alogliptin is not likely to adversely affect the renal function. In addition, similar results were observed in the subjects with stage 3 or worse CKD in this study, which strongly supports the safety of alogliptin. The disposition of alogliptin has been examined for different levels of the renal function, and the relationship between the level of the renal function and the dose of alogliptin has been clarified. The absence of accumulation has also been shown in simulation experiments, although these studies were based on single-dose administration (15, 29) . Moreover, in addition to its hypoglycemic effects, the multifaceted extrapancreatic actions, including the improvement of lipid profiles or hypotensive actions mediated by the inhibition of reabsorption of sodium in the kidneys, of alogliptin have been reported, although in a small number of patients (24, 30, 31) . While it is unknown if these actions result in renal protection, no significant changes were observed in the lipid profiles or blood pressure, and neither blood pressure nor the lipid levels were correlated with the rate of change in eGFR in this study.
The natural history of diabetic nephropathy is generally long. However, it is widely known that many patients clearly exhibit more rapid progression of the disease (1, 32) . Although the rapidly progressive type has not been clearly defined and its causes are unknown, patients whose GFR decreases by 3-5 mL/min/1.73 mm 2 or more per year are generally considered to have the condition. In our study, we defined subjects whose GFR decreased by 5 mL/min/1.73 mm 2 or more per year as belonging to the rapid decliner group for the analysis. The results showed that the GFR, which continued to decrease before treatment with alogliptin, stopped declining after the start of treatment and showed a tendency, although slight, to increase during the six months of treatment. Comparing the clinical background factors of the subjects in the rapid decliner group with those of the remaining patients, only diastolic blood pressure was found to show a significant difference. Diastolic blood pressure was significantly lower in the rapid decliner group; however, this cannot be considered a sufficient factor to explain the improvement in the speed of decrease in eGFR (33) . Moreover, the presence or absence of treatment with ARBs was not related to changes in eGFR. Based on these results, it is possible that alogliptin itself contributed to the improvement of eGFR in the rapid decliner group.
In addition, the analysis of early decliners suggested that the effects of alogliptin are not influenced by the baseline eGFR or the presence or absence of proteinuria.
The correlation between the rate of decrease in eGFR and the baseline systolic blood pressure indicates that patients with higher blood pressure experience more severe exacerbation of the renal function, as supported by various studies. Our results thus confirmed the importance of lowering blood pressure for maintaining the renal function. In many of the 36 subjects examined in this study, the blood pressure was controlled to less than 125 mmHg, according to the Japanese guidelines for CKD. However, we speculate that blood pressure was poorly controlled in some subjects and that the renal function of these subjects tended to deteriorate.
The UACR values continued to increase before treatment with alogliptin, then started to decline after the start of treatment. Considering the renal protective effects of alogliptin, this result provides significant confirmation of the maintenance of the eGFR values in all subjects. Although other DPP-4 inhibitors have been reported to decrease the UACR, to the best of our knowledge, this is the first report of a reduction in UACR due to alogliptin treatment (19, 34, 35) .
Many factors of the mechanisms underlying the renal protective effects of DPP-4 inhibitors (including alogliptin) remain unknown. Possible mechanisms include the resolution of glucose toxicity accompanied by an improvement in blood glucose variability (28). Improving the blood glucose level is well known to have a secondary effect of inhibiting the progression of complications (4, 6) . Although there are no clear data concerning blood pressure, improvements in the balance of body fluid volume due to the promotion of sodium excretion by alogliptin may also contribute to renal protection (17, 30, 36) . According to in vitro data, the glucagon-like peptide-1 (GLP-1) receptor is expressed in the kidneys; therefore, the kidney is the organ with the highest DPP-4 activity (37). For these reasons, the kidneys are likely to be a major target of the extrapancreatic effects of incretins. There are reports suggesting that, when activated by DPP-4 inhibitors, the level of GLP-1 is increased locally in the kidneys, producing anti-inflammatory effects and promoting antioxidative actions (16-21, 23, 38-41) .
There are only a small number of reports on the direct renal protective effects of DPP-4 inhibitors, including alogliptin, in patients with diabetic nephropathy. Extensive research on these effects should be conducted, including ani-mal and clinical studies.
In this study, we administered alogliptin in 36 patients with type 2 diabetes accompanying CKD who were receiving treatment with existing diabetes drugs and diet therapy. Neither the blood glucose levels nor renal function were exacerbated before or after the start of treatment. The results of this study suggest that alogliptin can be administered safely in CKD patients. Furthermore, we cannot deny the possibility that alogliptin may delay the progression of diabetic nephropathy, independent of the levels of blood glucose, blood pressure and lipids. However, although we expected alogliptin to exhibit renal protective effects, we were unable to detect statistically significant differences. One reasons for this finding is that there are few registered cases. Additional reports on the renal protective effects of alogliptin are needed.
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